For adults with neuromyelitis optica spectrum disorder (NMOSD), rituximab and Uplizna (inebilizumab) work equally well to prevent disease relapses, but Uplizna appears to be safer because it causes fewer infusion-related side effects. Those are the main findings of a real-world study analyzing data from more than 250 NMOSD…
Uplizna
Note: This column describes the author’s own experiences with Uplizna (inebilizumab-cdon). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I had a rough summer. After enduring three major attacks from my neuromyelitis optica spectrum disorder (NMOSD),…
Uplizna (inebilizumab) treatment markedly reduces the number of several subsets of immune B-cells that are linked to disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), trial data show. The therapy also lowers levels of the self-reactive antibodies against the AQP4 protein that drive most NMOSD cases,…
Long-term treatment with Uplizna (inebilizumab) was well tolerated and led to sustained disease control for adults with neuromyelitis optica spectrum disorder (NMOSD). That’s according to final data from the open-label extension period of the Phase 2/3 N-MOmentum clinical trial (NCT02200770), top-line data of which supported the therapy’s…
Health Canada has approved Uplizna (inebilizumab-cdon) to treat adults in the country with neuromyelitis optica spectrum disorder (NMOSD) who test positive for disease-driving anti-aquaporin-4 (AQP4) antibodies. The decision adds Canada to the list of nations where the medication is now available. The intravenous or into-the-vein infusion, developed by…
Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…
Treatment with Uplizna (inebilizumab-cdon) effectively prevented disease attacks and disability worsening for Asian people with neuromyelitis optica spectrum disorder (NMOSD) in the Phase 2/3 N-MOmentum clinical trial, a new analysis found. “In the Asian [patient] subgroup, the risk of NMOSD attacks was reduced with [Uplizna] versus placebo ……
An international team of experts has published evidence-based recommendations for how to best treat people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for aquaporin-4 immunoglobulin G (AQP4-IgG), the most common type of disease-driving antibody. The consensus statements were described in the study “International Delphi…
Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…
Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…
Recent Posts
- NMOSD: A full-time job with no pay, no vacation time, and lousy benefits
- Use of umbilical cord cells shown to safely cut relapses in NMOSD in trial
- The 3-inch high heels that were an act of rebellion against NMOSD
- 2 NMOSD drugs show equal power at preventing disease relapses
- Confessions of the kind of NMOSD patient doctors warn their interns about